The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Severe Acute Respiratory-Syndrome Treatment Market From 2026 To 2030?
The severe acute respiratory-syndrome treatment market has experienced rapid expansion in its scale over the past few years. Projections indicate its value will increase from $3.94 billion in 2025 to $4.53 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.2%. Factors contributing to this historical expansion include outbreaks of SARS-CoV and MERS-CoV, the broadening of hospital-based treatments, regulatory approvals for antiviral drugs, an increase in ICU capacity, and various awareness campaigns.
The severe acute respiratory-syndrome treatment market size is expected to experience significant expansion in the coming years. Its value is projected to reach $8.33 billion by 2030, progressing at a compound annual growth rate (CAGR) of 16.4%. This growth in the forecast period can be attributed to factors such as AI-assisted treatment protocols, the development of novel antivirals, critical care enabled by telemedicine, global pandemic preparedness programs, and investment in rapid diagnostics and treatment monitoring. Major trends observed within the forecast period encompass antiviral drug therapies, monoclonal antibodies, convalescent plasma therapy, the integration of tele-ICU, and AI-based treatment monitoring.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13027&type=smp
What Key Factors Are Shaping The Severe Acute Respiratory-Syndrome Treatment Market Landscape?
The severe acute respiratory syndrome treatment market is expected to grow as the occurrence of respiratory diseases rises. Respiratory diseases are defined as a range of medical conditions that impact the respiratory system, which is responsible for breathing and facilitating gas exchange between the body and its environment. Treatment for severe acute respiratory syndrome is utilized in these conditions to alleviate symptoms, prevent respiratory failure, reduce inflammation, and maintain oxygen levels. For instance, in December 2023, according to the National Library of Medicine, a US-based medical library, the worldwide count of chronic obstructive pulmonary disease (COPD) cases for individuals aged 25 and older is projected to increase by 23% by 2050, reaching nearly 600 million. Therefore, the increasing incidence of respiratory diseases is driving the expansion of the severe acute respiratory syndrome treatment market.
What Segment Categories Shape The Severe Acute Respiratory-Syndrome Treatment Market Segment Landscape?
The severe acute respiratory-syndrome treatment market covered in this report is segmented –
1) By Drug Class: Antibiotics, Antiviral, Corticosteroids, Monoclonal Antibodies, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV), Severe Acute Respiratory Syndrome COVID-19 2 (SARS-CoV-2)
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Antiviral: Nucleoside Analogs, Protease Inhibitors
3) By Corticosteroids: Systemic Corticosteroids, Inhaled Corticosteroids
4) By Monoclonal Antibodies: Neutralizing Antibodies, Non-Neutralizing Antibodies
5) By Other Drug Classes: Immunomodulators, Supportive Medications
What Market Trends Are Affecting The Severe Acute Respiratory-Syndrome Treatment Market?
Major companies in the severe acute respiratory syndrome treatment market are concentrating on technological innovations, such as oral antiviral therapies aimed at inhibiting viral replication and lessening disease severity. This focus responds to the escalating demand prompted by recurring coronavirus outbreaks and the pressing requirement for efficacious outpatient treatments. A notable illustration is the launch of Ensitrelvir by Shionogi & Co., Ltd., a Japan-based pharmaceutical company, in September 2025. This marked the introduction of the first oral antiviral therapy approved for both the prevention and treatment of SARS-CoV infections. Ensitrelvir operates by specifically inhibiting the 3C-like protease, an enzyme vital for viral replication, thereby offering a targeted mechanism that diminishes viral load and mitigates symptoms more effectively than traditional supportive care. Its formulation for simple oral administration enables wider community access and prompt intervention to prevent severe disease progression, representing a crucial stride in managing SARS amid evolving viral strains and healthcare necessities.
Who Are The Companies Operating Across The Severe Acute Respiratory-Syndrome Treatment Market Value Chain?
Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero Labs Ltd., Alexion Pharmaceuticals Inc., Cadila Healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, Panacea Biotec Limited, CureVac N.V., Inovio Pharmaceuticals Inc., Chimerix Inc.
Get The Full Severe Acute Respiratory-Syndrome Treatment Market Report:
Which Region Represents The Largest Share Of The Severe Acute Respiratory-Syndrome Treatment Market?
North America was the largest region in the severe acute respiratory syndrome treatment market in 2025. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the severe acute respiratory-syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Severe Acute Respiratory-Syndrome Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Severe Acute Respiratory-Syndrome Treatment Market 2026, By The Business Research Company
Acute Respiratory Distress Syndrome Ards Market Report 2026
Respiratory Disease Drugs Market Report
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Hospice Care Market Report
https://www.thebusinessresearchcompany.com/report/hospice-care-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model